Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 18/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 15/20 | 1.00 |
| ▸ | OXTR | P30559 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7339573 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL29373157 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL1649340 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL29377065 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL29387791 | 0.92 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL8317084 | 0.88 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL8313791 | 0.88 | AVPR2 (0.83) | AVPR2AVPR1A | |
| SCHEMBL8314637 | 0.87 | AVPR2 (0.88) | AVPR2AVPR1AOXTR | |
| SCHEMBL7338291 | 0.85 | AVPR2 (0.86) | AVPR2AVPR1AOXTR | |
| SCHEMBL8317046 | 0.85 | AVPR2 (0.85) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-0636625-B1 | Tricyclic diazepines vasopressin and oxytocin antagonists | AMERICAN CYANAMID CO (US) | 1999-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | AVPR2 1018/4885AVPR1A 1282/4885OXTR 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.